A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): The liver metastasis and the outcome

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Zhu, Jiang ^a   Yang, Yu ^a   Zhou, Lin ^a   Jiang, Ming ^a   Hou, Mei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; SUNITINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HEMATOLOGIC DISEASE; HUMAN; LIVER METASTASIS; MALE; NAUSEA; NEUTROPENIA; NEUTROPHIL; OVERALL SURVIVAL; RASH; RECURRENT CANCER; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; CHI SQUARE DISTRIBUTION; DISEASE COURSE; KAPLAN MEIER METHOD; LIVER TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; TIME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953728645     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-199     Document Type: Article

References (21)

1. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000, 15(4):1293-1301.
2. Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl Surg 1996, 33:817-872. 10.1016/S0011-3840(96)80013-X, 8885853.
3. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279(5350):577-580. 10.1126/science.279.5350.577, 9438854.
4. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002, 160(5):1567-1572. 1850861, 12000708.
5. DeMatteo RP, Heinrich MC, El Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002, 33(5):466-477. 10.1053/hupa.2002.124122, 12094371.
6. Langer C, Gunawan B, Schuler P, Huber W, Füzesi L, Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003, 90(3):332-339. 10.1002/bjs.4046, 12594669.
7. Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R, Swallow CJ. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001, 8(1):50-59. 10.1007/s10434-001-0050-4, 11206225.
8. DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001, 234(4):540-547. 10.1097/00000658-200110000-00013, 1422077, 11573047.
9. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 2000, 88(1):66-74. 10.1002/(SICI)1097-0142(20000101)88:1<66::AID-CNCR10>3.0.CO;2-0, 10618607.
10. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344(14):1052-1056. 10.1056/NEJM200104053441404, 11287975.
11. Demetri GD, von Mehren M, Blanke CD, Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347(7):472-480. 10.1056/NEJMoa020461, 12181401.
12. Blanke CD, Demetri GD, Von Mehren M. Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate. J Clin Oncol 2006, 24(18S):9528.
13. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K. American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373(9669):1097-104. 10.1016/S0140-6736(09)60500-6, 19303137.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216. 10.1093/jnci/92.3.205, 10655437.
15. Kindblom LG, Remotti HE, Aldenberg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998, 152(5):1259-1269. 1858579, 9588894.
16. Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2001, 2:485-491. 10.1007/s11864-001-0070-0, 12057094.
17. Zacherl J, Zacherl M, Scheuba C, Steininger R, Wenzl E, Mühlbacher F, Jakesz R, Längle F. Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma. J Gastrointest Surg 2002, 6(5):682-689. 10.1016/S1091-255X(01)00075-0, 12399057.
18. Hoe AL, Royle GT, Taylor I. Breast liver metastases: incidence, diagnosis and outcome. J R Soc Med 1991, 84(12):714-716. 1295516, 1774744.
19. Choi WH, Kim S, Hyung WJ, Yu JS, Park CI, Choi SH, Noh SH. Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy. Yonsei Med J 2009, 50(3):437-40. 10.3349/ymj.2009.50.3.437, 2703769, 19568608.
20. Zhu J, Wang Y, Hou M, Li HY, Zhang J. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection. Oncology 2007, 73(5-6):324-327. 10.1159/000134475, 18497504.
21. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006, 368(9544):1329-1338. 10.1016/S0140-6736(06)69446-4, 17046465.